Lymphangioleiomyomatosis, or LAM, is a rare and progressive lung disease that primarily affects women during their childbearing years. Treatment focuses on preserving lung function, managing symptoms, and preventing serious complications. While there is no cure yet, recent advances have brought new hope through approved medications and ongoing research into innovative therapies.

Understanding Treatment Goals for LAM

When a woman receives a diagnosis of lymphangioleiomyomatosis, the medical team faces a challenging task. This rare disease causes abnormal smooth muscle-like cells to grow out of control in the lungs, kidneys, and lymphatic system. Over time, these cells create cysts in the lungs, damage healthy tissue, and reduce the amount of oxygen that reaches the body’s organs. Treatment aims to slow down this destructive process, preserve as much lung function as possible, and help patients maintain their quality of life for as long as possible.^[1][2]

The approach to treating LAM is highly individual. Not every patient experiences the disease in the same way. Some women have mild symptoms that progress slowly over many years, while others face rapid decline in lung function. Doctors must carefully consider each patient’s age, overall health, the severity of their symptoms, and how quickly the disease is advancing. Treatment plans often evolve over time as the disease changes and as new therapies become available through research.^[3]

Medical societies and expert panels have developed guidelines based on the latest evidence to help doctors make treatment decisions. These recommendations draw from clinical trials, patient registries, and the collective experience of specialized LAM clinics around the world. At the same time, researchers continue to investigate new drugs and therapies through clinical trials, searching for better ways to control this complex disease. Patients today have access to treatments that were not available even a decade ago, and the outlook continues to improve as scientific understanding grows.^[4][5]

Standard Medical Treatment for LAM

The foundation of LAM treatment now centers on a medication called sirolimus, also known by the name rapamycin or the brand name Rapamune. In May 2015, sirolimus became the first drug officially approved by the United States Food and Drug Administration specifically for treating LAM. This represented a major milestone for patients and their doctors, providing an evidence-based therapy that targets the underlying disease process rather than just managing symptoms.^[10][12]

Sirolimus belongs to a class of medicines called mTOR inhibitors. The name comes from the cellular pathway it blocks: mammalian target of rapamycin. In LAM, genetic mutations cause the mTOR pathway to become overactive, which allows LAM cells to multiply uncontrollably. By inhibiting this pathway, sirolimus suppresses the growth and movement of these abnormal cells throughout the body. The drug has been shown to stabilize lung function in most women with LAM, meaning it slows or stops the decline in breathing capacity that would otherwise occur. It can also shrink kidney tumors called angiomyolipomas, reduce fluid accumulation around the lungs and in the abdomen, and improve some quality-of-life measures.^[12][13]

The evidence supporting sirolimus comes primarily from a landmark clinical trial called MILES (Multicenter International Safety and Efficacy of Sirolimus in LAM). This Phase III trial was a rigorous, double-blind, placebo-controlled study that followed 89 patients over 12 months. Women taking sirolimus experienced slower decline in lung function compared to those receiving a placebo. Importantly, the study showed that sirolimus treatment must be continued long-term. When the drug was stopped, lung function began declining again at the same rate seen in untreated patients. This means sirolimus is suppressive rather than curative—it controls the disease but does not eliminate it.^[12][13]

Like all powerful medications, sirolimus comes with potential side effects that patients and doctors must manage carefully. Common side effects include mouth ulcers (painful sores in the mouth), acne, high blood cholesterol levels, swelling of the mouth and lips, diarrhea, nausea, and fluid buildup in the legs. The drug can also affect the ovaries, liver, and kidneys. Because sirolimus suppresses certain parts of the immune system, it may increase the risk of infections. Many patients experience an adjustment period when starting the medication, followed by stabilization of side effects over time. Regular blood tests are necessary to monitor drug levels and check for complications. Despite these challenges, most patients taking sirolimus report that the benefits in terms of preserved lung function and reduced complications outweigh the inconveniences of side effects.^[12][16]

Another mTOR inhibitor called everolimus (brand name Afinitor) is sometimes used to treat LAM, although it is not officially FDA-approved for this specific purpose. Everolimus is a derivative of sirolimus with very similar functions and side effects. It has been shown to be effective for treating the kidney tumors (angiomyolipomas) that occur in many LAM patients. A four-year Phase III clinical trial demonstrated that everolimus could reduce the volume of these kidney tumors in 54% of patients during the initial study, with 58% achieving tumor response during the extension phase. The most commonly reported side effects included mouth sores, high cholesterol, acne, inflammation of the mouth, and respiratory infections. Doctors may choose everolimus in certain situations based on patient-specific factors, though sirolimus remains the primary recommended mTOR inhibitor for LAM.^[12][14]

Beyond mTOR inhibitors, several other medications play important supporting roles in LAM management. Bronchodilators are inhaled medications that help relax and open the airways, making breathing easier. These work similarly to asthma medications and can reduce wheezing and shortness of breath during daily activities. Many women with LAM find that bronchodilator inhalers such as albuterol provide meaningful relief from breathlessness. Longer-acting bronchodilators that only need to be taken once or twice daily are often prescribed for ongoing symptom control.^[10][12]

When oxygen levels in the blood drop too low, supplemental oxygen becomes necessary. Oxygen therapy can be prescribed for use during physical exertion, while sleeping, or eventually full-time as the disease progresses. Small, portable oxygen concentrators and cylinders allow patients to remain mobile and active despite needing oxygen support. Supplemental oxygen makes a tremendous difference in quality of life—it reduces breathlessness, prevents strain on the heart, allows better exercise tolerance, and helps patients maintain their independence and daily activities. Proper oxygen supplementation is crucial for protecting organs from damage due to low oxygen levels.^[10][12]

Some doctors have explored hormone-based treatments based on the observation that LAM almost exclusively affects women of childbearing age and may worsen during pregnancy. The female hormone estrogen is believed to contribute to LAM cell growth. Various hormonal approaches have been tried, including progesterone (medroxyprogesterone), drugs that suppress estrogen production (gonadotropin-releasing hormone agonists), and aromatase inhibitors like letrozole that block estrogen formation. However, the evidence supporting these treatments is limited. Recent case series have not shown clear benefits from progesterone, and tamoxifen appeared ineffective and is not recommended. Surgical removal of the ovaries (oophorectomy) has been observed to slow disease progression in some postmenopausal women compared to premenopausal patients, but this remains an area of ongoing investigation rather than standard practice.^[5][14]

LAM patients require comprehensive supportive care beyond medications. Regular vaccinations are essential—yearly flu shots, pneumonia vaccines, and COVID-19 vaccines help protect vulnerable lungs from respiratory infections. Smoking cessation is absolutely critical, as smoking accelerates lung damage. Medications to prevent bone loss (osteoporosis) may be needed, especially in patients taking medications that affect bone density or those who avoid estrogen-containing therapies. Patients should also avoid medications containing estrogen, such as certain birth control pills or hormone replacement therapies.^[14][17]

For patients with severe, advanced lung damage, lung transplantation may become necessary. A lung transplant involves surgically replacing one or both diseased lungs with healthy donor lungs. This is a major operation with significant risks, but it can extend life and improve quality of life for carefully selected patients with end-stage LAM. The decision to proceed with transplant evaluation involves many factors including age, overall health, severity of lung damage, and absence of other major medical problems. Patients listed for transplant need to maintain their strength and fitness as much as possible while waiting for a donor. Important to note, because LAM cells do not originate in the lungs themselves, there is a possibility of cysts returning even after transplantation, though transplant still offers significant benefit for many patients.^[5][10]

LAM often causes serious complications that require specific treatments. The most common complication is pneumothorax, a collapsed lung that occurs when a cyst bursts and air leaks into the space around the lung. Over half of all women with LAM will experience at least one pneumothorax, and recurrences are common. Treatment depends on severity and may include observation for small collapses, insertion of a chest tube to remove the leaked air, or surgical procedures to prevent future collapses. Chemical or surgical pleurodesis—a procedure that causes the lung to stick to the chest wall—is sometimes performed to reduce the risk of recurrent pneumothorax.^[3][14]

Fluid accumulation around the lungs (chylothorax) or in the abdomen (chylous ascites) represents another complication requiring intervention. The fluid is often chyle, a milky substance rich in fats from the lymphatic system. Treatment may include drainage procedures to remove the fluid and relieve symptoms, dietary modifications such as a low-fat diet supplemented with medium-chain triglycerides, or medications. For kidney angiomyolipomas that are large or bleeding, treatment options include mTOR inhibitors to shrink them or procedures to block blood supply to the tumor or surgically remove it.^[3][14]

Promising Therapies in Clinical Trials

While sirolimus represents a significant advance, it is not a cure, and not all patients respond equally well. Scientists continue to search for additional treatments that might work better, target different aspects of the disease, or help patients who don’t tolerate mTOR inhibitors. Several promising approaches are currently being tested in clinical trials around the world.^[13]

One area of investigation focuses on other drugs that might interfere with LAM cell survival and spread. Chloroquine, a medication traditionally used to treat malaria, is being studied for its ability to inhibit a cellular process called autophagy. Autophagy is a mechanism cells use to recycle their components and survive under stress. LAM cells appear to rely heavily on autophagy, and blocking this process might slow their growth and spread. Chloroquine inhibits autophagy and is being evaluated in clinical trials to see if it provides benefit for LAM patients beyond what mTOR inhibitors achieve.^[13][14]

Doxycycline, an antibiotic with additional properties beyond fighting bacteria, has attracted interest as a potential LAM therapy. Beyond its antimicrobial effects, doxycycline can inhibit enzymes called matrix metalloproteinases that break down the structural proteins in lung tissue. LAM cells produce high levels of these enzymes, which may contribute to lung destruction and cyst formation. By blocking these enzymes, doxycycline might slow the breakdown of lung tissue. Additionally, doxycycline has anti-inflammatory properties and may affect other pathways involved in LAM progression. Clinical trials are investigating whether adding doxycycline to standard mTOR inhibitor therapy provides additional benefit.^[13]

Statins, medications commonly prescribed to lower cholesterol, are also being explored for LAM. These drugs, which include simvastatin and other related compounds, have effects beyond cholesterol reduction. They can modulate immune responses, reduce inflammation, and potentially affect cell growth pathways. Some laboratory research suggests statins might inhibit LAM cell proliferation and movement. Clinical trials are examining whether statins, particularly simvastatin, can slow disease progression in LAM patients, either alone or in combination with mTOR inhibitors.^[13]

The hormone connection in LAM continues to drive research into antihormonal therapies. Since LAM almost exclusively affects women of reproductive age and may worsen during pregnancy, hormones likely play a significant role. Aromatase inhibitors such as letrozole work by blocking the enzyme aromatase, which converts other hormones into estrogen. By reducing estrogen levels throughout the body, these drugs might slow LAM cell growth. Several clinical trials have investigated aromatase inhibitors, though results have been mixed and more research is needed to determine their place in LAM treatment.^[14]

Nintedanib, a drug approved for treating other lung diseases such as idiopathic pulmonary fibrosis, has been tested in LAM. Nintedanib is a multikinase inhibitor, meaning it blocks several different enzymes (kinases) that are involved in cell growth, blood vessel formation, and tissue scarring. A small clinical trial (N=30) evaluated nintedanib in women with LAM (both sporadic and TSC-associated). The study examined whether this drug could slow lung function decline and reduce symptoms. Results from such trials help researchers understand whether drugs successful in other lung diseases might also benefit LAM patients.^[14]

Research into LAM treatments goes beyond just testing new drugs. Scientists are trying to understand fundamental mechanisms of the disease that could be targeted therapeutically. These include how LAM cells manage to spread throughout the body (metastasize), how they destroy normal lung tissue, how they stimulate the growth of new blood vessels and lymphatic vessels, and exactly how hormones regulate their behavior. Addressing these poorly understood areas could lead to entirely new treatment approaches in the future.^[13]

Clinical trials for LAM are conducted in phases, each with a specific purpose. Phase I trials focus primarily on safety—determining whether a new drug or therapy is safe enough to give to patients, identifying the right dose range, and watching for serious side effects. These are typically small studies involving 20-30 patients. Phase II trials are larger, involving perhaps 50-100 patients, and focus on whether the treatment actually works—does it improve lung function, reduce symptoms, shrink tumors, or provide other measurable benefits? These trials also continue to monitor safety. Phase III trials are the largest and most rigorous, often involving hundreds of patients. They compare the new treatment directly against the current standard of care or a placebo to definitively determine if the new approach is better. The MILES trial that led to sirolimus approval was a Phase III trial.^[13]

Clinical trials for LAM are conducted at specialized medical centers around the world, including locations in the United States, Europe, and other regions. Many trials are coordinated through networks of LAM clinics that have expertise in this rare disease. Patient eligibility for trials varies depending on the specific study. Some trials accept only patients with certain disease severity—for example, those with moderately severe LAM but not extremely mild or extremely advanced disease. Other factors affecting eligibility might include whether patients are already taking sirolimus, their oxygen requirements, history of complications, and whether they have sporadic LAM or TSC-associated LAM. Patients interested in clinical trials should ask their LAM specialist about currently enrolling studies or can search for trials through resources like clinicaltrials.gov.^[12]

An important area of current investigation is whether treating LAM earlier, before significant lung damage occurs, might prevent disease progression more effectively. An ongoing clinical trial is evaluating whether starting sirolimus in patients with relatively preserved lung function—before they become severely symptomatic—can prevent or delay the lung damage that would otherwise occur. This preemptive treatment approach represents a shift from waiting until patients are already struggling with symptoms before beginning therapy. Results from such studies could change practice patterns in the future.^[12]

Most Common Treatment Methods

• mTOR Inhibitor Therapy
  • Sirolimus (rapamycin) – FDA-approved first-line treatment that stabilizes lung function by inhibiting the overactive mTOR pathway in LAM cells
  • Everolimus – Similar mTOR inhibitor used especially for kidney tumor (angiomyolipoma) reduction
  • Long-term continuous use required to maintain benefits
  • Regular blood monitoring needed to adjust dosing and check for side effects
• Bronchodilator Therapy
  • Short-acting bronchodilators like albuterol for immediate symptom relief
  • Long-acting bronchodilators for daily maintenance therapy
  • Combination inhalers containing multiple bronchodilator medications
  • Help relax airway muscles and improve breathing
• Oxygen Therapy
  • Initially used during exertion or sleep when oxygen levels drop
  • May progress to full-time oxygen as disease advances
  • Delivered through portable oxygen concentrators or cylinders
  • Improves quality of life, exercise tolerance, and protects organs from low oxygen damage
• Surgical Interventions
  • Pleurodesis procedures to prevent recurrent lung collapse
  • Drainage procedures for fluid accumulation around lungs or in abdomen
  • Treatment of bleeding kidney tumors through embolization or surgical removal
  • Lung transplantation for end-stage disease
• Hormone-Based Approaches
  • Aromatase inhibitors like letrozole to reduce estrogen levels
  • Avoidance of estrogen-containing medications such as certain birth control pills
  • Consideration of hormonal influences when planning pregnancy
• Supportive Care
  • Pulmonary rehabilitation programs to maintain strength and exercise capacity
  • Vaccinations against respiratory infections (flu, pneumonia, COVID-19)
  • Smoking cessation support
  • Osteoporosis prevention and treatment
  • Nutritional support and dietary modifications for lymphatic complications

Managing Life with LAM

Living with lymphangioleiomyomatosis requires ongoing medical care and lifestyle adjustments. Regular follow-up appointments with a pulmonary specialist experienced in LAM are essential. These visits typically include pulmonary function tests to monitor breathing capacity, oxygen saturation measurements, and sometimes imaging studies to track cyst development or kidney tumors. The frequency of monitoring depends on disease severity and stability, but most patients are seen every few months to annually.^[17]

Many everyday decisions require thoughtfulness for LAM patients. Air travel can be challenging because cabin pressure changes may increase the risk of pneumothorax. Patients should discuss travel plans with their doctor, especially for long flights or travel to remote areas where medical care might not be readily available. Similarly, activities involving significant altitude changes or scuba diving carry increased risks. Heavy lifting and straining should be avoided as these can increase pressure in the chest and potentially trigger lung collapse.^[17]

Pregnancy is a complex decision for women with LAM. The disease often worsens during pregnancy due to hormonal changes and the increased oxygen demands of supporting both mother and baby. Women with normal or near-normal lung function may be able to safely carry a pregnancy, but this requires close coordination between the patient’s LAM specialist, an endocrinologist (hormone specialist), and a high-risk obstetrician. Some women choose alternatives such as adoption or surrogacy. Each situation is unique and requires careful individualized counseling.^[19]

Exercise and physical activity remain important even as LAM progresses. Pulmonary rehabilitation programs provide supervised exercise training tailored to patients with lung disease. Trained staff monitor oxygen levels and heart rate during exercise to ensure safety and help patients understand what level of activity is appropriate. Rehabilitation helps maintain muscle strength, improve exercise tolerance, and optimize quality of life. For patients awaiting lung transplant, staying as strong and fit as possible improves outcomes after surgery.^[16]

The emotional and psychological impact of living with a rare, progressive disease cannot be understated. Many women experience grief, fear, anger, frustration, or depression at various stages of their journey. These feelings are normal responses to loss of health and the uncertainties of chronic illness. Connecting with other LAM patients through support groups, either in person or online, can provide validation, practical advice, and emotional support. Professional counseling or therapy may help some patients develop coping strategies. Open communication with family and friends about needs and feelings is also important.^[16]

The prognosis for LAM has improved significantly over recent decades. In the past, survival after diagnosis averaged around 10 years. Today, median survival is estimated at more than 20 years after diagnosis, with transplant-free survival probability of 94% at 5 years, 85% at 10 years, 75% at 15 years, and 64% at 20 years. These statistics represent averages—individual outcomes vary considerably. Disease progression is different for everyone; some women experience slow progression over many years, while others face more rapid decline. Premenopausal women tend to have faster rates of lung function decline than postmenopausal women, reinforcing the role of hormones in disease activity.^[3]